An emerging biopharma company partnered with IQVIA to create a digital-first caregiver support program for children with a rare pediatric brain disease requiring daily injections. The platform provided educational resources, injection training, tailored action plans, adherence tools, and access to nurse support. Behavioral science informed the design, ensuring interventions were personalized and effective. The program achieved a 95% compliance rate, starting in two countries and expanding to six more. By addressing both practical and emotional challenges, it improved caregiver confidence, treatment adherence, and ultimately patient outcomes.

Join for free to read